Four CDMOs to watch as biopharma outsourcing grows

The article lists four contract development and manufacturing organizations (CDMOs) that biopharma companies can partner with as demand for external development and manufacturing rises.

Lonza, based in Basel, Switzerland, is highlighted as one of the largest CDMOs, operating more than 30 sites on five continents and employing about 20,000 people. In the United States it runs facilities in Cambridge, MA; Durham, NC; Morristown, NJ; and Vacaville, CA, and serves customers ranging from emerging biotech firms to global pharma majors. Its service platforms cover integrated biologics, advanced synthesis and specialized modalities, with capabilities that include mammalian biologics, small molecules, potent APIs, bioconjugates, mRNA, microbial products and cell and gene therapies.

Samsung Biologics is also mentioned, noting its recent announcement of a planned acquisition of another CDMO, signaling continued consolidation in the sector. The piece suggests that as biopharma companies look to bring more drugs to market, they will likely evaluate these and other CDMOs for development and manufacturing support.